EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comorbidities at MS Diagnosis and Their Association With Treatment Persistence: Real‐World Clinical Data

Henrik Ahvenjärvi, Ida Lund, Anne M Portaankorva, Johanna Krüger, Mervi Ryytty

Brain and Behavior · 2026

DOI: 10.1002/brb3.71253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, 2026. Verfasst von Henrik Ahvenjärvi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit of Clinical Medicine, Neurology, University of Oulu, Oulu, Finland. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Migraine Disorders, Depression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Research funding, Finnish Neurological Society, Finnish Cultural Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The objectives were to evaluate the prevalence of comorbidities at the time of multiple sclerosis (MS) diagnosis in a Finnish cross‐sectional cohort and to analyze whether comorbidities at diagnosis associate with clinical characteristics, treatment delays, initial disease‐modifying treatment (DMT) choice, DMT persistence, and disease activity.

Methods

Patients with relapsing‐remitting MS (RRMS) were recruited during their appointments at the neurology outpatient clinic of the Oulu University Hospital, Finland, between the years 2018 and 2022. The data was gathered from the hospital medical records.

Results

The study cohort consisted of 421 Finnish RRMS patients, of whom 51.8% had at least one or more comorbidity at the time of MS diagnosis. Depression (16.2%) and migraine (11.6%) were the most common comorbidities. Medium‐efficacy injectable DMTs (interferon‐β and glatiramer acetate) were associated with lower treatment persistence in patients with any comorbidity or psychiatric comorbidity during the 4‐year follow‐up. Among patients with psychiatric comorbidity, the rate of DMT discontinuation was high shortly after the DMT initiation, and the annualized relapse rate at the start of the DMT was higher compared with those without psychiatric comorbidity (1.3 [SD 0.78] vs. 1.1 [SD 0.74], p = 0.026).

Conclusion

Comorbidities, especially psychiatric diseases, are associated with lower persistence on injectable DMTs. As comorbidities complicate the treatment of RRMS, it is crucial to identify their role from early on.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingMigraine DisordersDepressionHumansFemaleFinlandMaleComorbidityAdultCross-Sectional StudiesMiddle AgedGlatiramer AcetateInterferon-betaPrevalenceTreatment Delay

Stichwörter der Autor:innen

comorbiditydisease activitymultiple sclerosispsychiatric diseasetreatment persistence

Substanzen

Glatiramer AcetateInterferon-beta

Autor:innen und Institutionen

  • Research Unit of Clinical Medicine, Neurology, University of Oulu, Oulu, Finland.
  • Clinical Neurosciences, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Neurocenter, Neurology, Oulu University Hospital, Oulu, Finland.
  • Medical Research Center, Oulu University Hospital, Oulu, Finland.

Förderung

  • State Research funding
  • Finnish Neurological Society
  • Finnish Cultural Foundation
  • Finnish MS Foundation
  • University of Oulu Scholarship Foundation
  • Pohjois-Pohjanmaan Rahasto
  • Suomen Kulttuurirahasto
  • Oulun Yliopiston Tukisäätiö

Zitieren

APA

Ahvenjärvi, H., Lund, I., Portaankorva, A. M., Krüger, J., & Ryytty, M. (2026). Comorbidities at MS Diagnosis and Their Association With Treatment Persistence: Real‐World Clinical Data. Brain and Behavior. https://doi.org/10.1002/brb3.71253

Vancouver

Ahvenjärvi H, Lund I, Portaankorva AM, Krüger J, Ryytty M. Comorbidities at MS Diagnosis and Their Association With Treatment Persistence: Real‐World Clinical Data. Brain and Behavior. 2026. doi:10.1002/brb3.71253

BibTeX
@article{Ahvenjrvi2026,
  author = {Ahvenjärvi, Henrik and Lund, Ida and Portaankorva, Anne M and Krüger, Johanna and Ryytty, Mervi},
  title = {Comorbidities at MS Diagnosis and Their Association With Treatment Persistence: Real‐World Clinical Data},
  journal = {Brain and Behavior},
  year = {2026},
  doi = {10.1002/brb3.71253}
}
Kostenlos starten →